Browsing by Author "Ivascenko, Tarass"

Now showing 1 - 2 of 2
  • No Thumbnail Available
    Item
    Atrial fibrillation, oral anticoagulants and health related quality of life
    (2018-12) Apsite, Ketija; Luriņa, Baiba; Tupahins, Andris; Voicehovskis, Vladimirs; Ivascenko, Tarass; Kalejs, Oskars; Lejnieks, Aivars; Faculty of Medicine; Department of Internal Diseases; Department of Doctoral Studies
    Introduction: Atrial fibrillation (AFib) is a disease that can influence the health related quality of life. Also oral anticoagulants can influence it both because of its therapeutic benefits or complications as well as how the anticoagulant usage influence the person's life style by regular laboratory test necessity or diet restrictions. Aim: Determine and analyze whether there is a statistically significant difference comparing health related quality of life between K vitamin antagonist, warfarin, users, novel anticoagulant (NOAC), rivaroxaban, dabigatran, users and patients, who do not use any kind of oral anticoagulant. Materials and methods: A cross-sectional analytic research was made in Pauls Stradins Clinical university hospital, Center of Cardiology in Riga, Latvia during the time period from October 2016 till June 2017. Persons with high-risk non-valvular atrial fibrillation were offered to participate in this research. If the person agreed, an oral interview with questions about disease anamnesis, demographic data, laboratory test results, echocardiography results, modified SF-36 survey, used oral anticoagulant type was held. Data were precised with the help of the case anamnesis information. For statistical data analysis was used SPSS Statistics database. Results: Altogether 218 patients were enrolled, of which 56.9% were female and 43.1% – male, mean age – 70.4 years, mean CHA2D2-VASc score – 4.4. Warfarin used 37.6%, 33.0% – novel oral anticoagulants, but 29.4% did not use any kind of oral anticoagulant. A statistically significant difference was discovered between the mean ranks in physical functioning sections comparing warfarin (mean rank 95.85) with NOACs (mean rank 124.57); p = 0.012. Also a statistically significant difference was in social functioning comparing warfarin (mean rank 96.16) with NOACs (mean rank 119.08); p = 0.026. Age had low negative correlation (r = −0.23) with physical functioning. Duration of atrial fibrillation diagnosis did not have correlations with the results. Conclusion: NOAC usage correlates with the best health related quality of life scores, gaining a statistically significant difference compared to warfarin users in physical functioning (warfarin – 95.85, NOACs – 124.57; p = 0.012) and social functioning mean ranks (warfarin – 95.16, NOACs – 119.08; p = 0.026). Age had low negative correlation with physical functioning scores.
  • No Thumbnail Available
    Item
    Oxidative stress, depression, and risk of recurrence of stable coronary heart disease
    (2021) Ivascenko, Tarass; Voicehovskis, Vladimirs V.; Voicehovska, Julija G.; Skesters, Andrejs; Apsite, Ketija; Grigorjeva, Julija; Kivite-Urtane, Anda; Pahomova, Natalija; Kalejs, Oskars; Rīga Stradiņš University
    Aim: The aim of the study was to investigate the relationships between a level of oxidative stress (OS), depression (D) and risk of recurrence of stable coronary heart disease (SCHD). Methods: A retrospective study was conducted on 174 participants, at the age 45+ years: 86 in-patients of the cardiology department with a recurrent SCHD and 88 in-patients of the cardiology department with primary SCHD. The severity of depressive symptoms was assessed using the long 30-item form of Geriatric Depression Scale (GDS), valid Latvian version of GDS-LAT. The blood samples were taken from each patient to measure oxidative stress parameters malondialdehyde (MDA) and glutathione peroxidase (GPx). Results: 83.9% of the sample had high level of MDA. In 72.4% of the sample the GPx level was normal, in 17.8% it was high and in 9.8% low. Slightly more than a half of the patients were experiencing depression (44.3% – mild D and 6.9% – severe D). GPx was found statistically differing between primary and recurrent SCHD (p = 0,003). Patients with both D and high GPx had 10.6 times higher chances of recurrent SHCD compared to those without D and normal GPx (p = patients with present D were experiencing both – high levels of MDA and GPx – more often than responders with no D, but this wasn’t statistically significant [p = 0.51]). Conclusion: In the present study it was found that level of antioxidant (AO) enzyme GPx was significantly higher in depressed patients with recurrent SCHD compared to patients without D and to patients with primary SCHD and patients with both D and high GPx had higher chances of recurrent SCHD compared to those without D and normal GPx. It could be supposed that GPx is a more significant marker of risk of D and recurrence of SCHD. The high level of MDA in most of both (primary and recurrent SCHD) groups patients could evidence that increased OS is a risk factor for CHD in general. Monitoring OS biomarkers seems to be important in the management of SCHD comorbidity with D. Further studies are warranted to confirm these findings.